Publications
Chad Thompson (162 POSTS)
2023 (12 POSTS)
In vitro transcriptomic analyses informing the mode of action of HFPO-DA (GenX) in the liver
Klaren WD, Heintz MM, East AW, Thompson CM, Haws LC. In vitro transcriptomic analyses informing the mode of action of HFPO-DA (GenX) in the liver. Poster presented at Society of Toxicology Annual Meeting, Nashville, TN, March 2023.
Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death
Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.
View AbstractAssessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans
Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.
View AbstractReliability assessment of guideline-based studies using systematic review critical appraisal tools
Choksi NY, Fitch S, Harris MA, Thompson CM, Wikoff DS. Reliability assessment of guideline-based studies using systematic review critical appraisal tools. Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.
An evaluation of risk assessments on hexavalent chromium [Cr(VI)]: The past, present, and future of mode of action research
Thompson CM, Wikoff DS, Proctor DM, Harris MA. An evaluation of risk assessments on hexavalent chromium [Cr(VI)]: The past, present, and future of mode of action research. Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.
Risk assessment of three smoke flavoring primary products currently under re-evaluation by EFSA
Franzen AC, Thompson CM, Brorby GP, Wikoff DS, Ilkbahar Z, Doepker C. Risk assessment of three smoke flavoring primary products currently under re-evaluation by EFSA. Poster presented at Society of Toxicology 62nd Annual Meeting, Nashville, TN, March 2023.
Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data”
Thompson CM, Proctor DM, Harris MA. 2023. Letter to “Chepelev et al. Establishing a quantitative framework for regulatory interpretation of genetic toxicity dose–response data: Margin of exposure case study of 48 compounds with both in vivo mutagenicity and carcinogenicity dose–response data.” Environ Mol Mutagen 64(4):259–260; doi: 10.1002/em.22537. PMID: 36916184.
2022 (7 POSTS)
Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA
Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.
View AbstractAssessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances
Lea IA, Pham LL, Antonijevic T, Thompson C, Borghoff SJ. 2022. Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances. Regul Toxicol Pharmacol 133(August):105190; doi: 10.1016/j.yrtph.2022.105190. PMID: 35662637.
View AbstractDevelopment of a putative adverse outcome pathway for neonatal mortality in rodents: Implications for human health risk assessments of PFAS
Rogers JM, Heintz MM, Thompson CM, Haws LC. Development of a putative adverse outcome pathway for neonatal mortality in rodents: Implications for human health risk assessments of PFAS. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.
View AbstractUse of targeted mode-of-action research to inform human health risk assessment of hexavalent chromium
Thompson CM, Chappell GA, Mittal L, Gorman B, Proctor DM, Haws LC, Harris MA. Use of targeted mode-of-action research to inform human health risk assessment of hexavalent chromium. Poster presented at Society of Toxicology Annual Meeting, San Diego, CA, March 2022.
View AbstractVariation in transcriptomic responses in the crypt and villus of mouse small intestine following oral exposure to hexavalent chromium
Chappell G, Wolf JC, Harris MA, Thompson CM. Variation in transcriptomic responses in the crypt and villus of mouse small intestine following oral exposure to hexavalent chromium. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.
View AbstractHFPO-DA (GenX) transcriptomic responses in pregnant and non-pregnant rat livers: Analyses to inform the role of maternal effects on neonatal toxicity
Heintz MM, Chappell GA, Thompson CM, Wolf JC, Rogers JM, Haws LC. HFPO-DA (GenX) transcriptomic responses in pregnant and non-pregnant rat livers: Analyses to inform the role of maternal effects on neonatal toxicity. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.
View AbstractCrypt and villus transcriptomic responses in mouse small intestine following oral exposure to hexavalent chromium
Chappell GA, Wolf JC, Thompson CM. 2021. Crypt and villus transcriptomic responses in mouse small intestine following oral exposure to hexavalent chromium. Toxicol Sci 186(1):43-57; doi: 10.1093/toxsci/kfab152. PMID: 34935971.
View Abstract2021 (5 POSTS)
A review of mammalian in vivo genotoxicity of hexavalent chromium: Implications for oral carcinogenicity risk assessment
Thompson CM, Aardema MJ, Heintz MM, MacGregor JT, Young RR. 2021. A review of mammalian in vivo genotoxicity of hexavalent chromium: Implications for oral carcinogenicity risk assessment. Crit Rev Toxicol 51(10)820-849; doi: 10.1080/10408444.2021.2000934. PMID: 35060824.
View AbstractInhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches
Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.
View AbstractButylated hydroxyanisole: Carcinogenic food additive to be avoided or harmless antioxidant important to protect food supply?
Felter SP, Zhang X, Thompson C. 2021. Butylated hydroxyanisole: Carcinogenic food additive to be avoided or harmless antioxidant important to protect food supply? Regul Toxicol Pharmacol 121(April):104887; doi: 10.1016/j.yrtph.2021.104887.
View AbstractDevelopment of updated RfD and RfC values for medium carbon range aromatic and aliphatic total petroleum hydrocarbon fractions
Thompson CM, Bhat VS, Brorby GP, Haws LC. 2021. Development of updated RfD and RfC values for medium carbon range aromatic and aliphatic total petroleum hydrocarbon fractions. J Air Waste Manag Assoc 71(12):1555–1567; doi: 10.1080/10962247.2021.1974123. PMID: 34469276.
View AbstractAssessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens
Chappell GA, Wikoff DS, Thompson CM. 2021. Assessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens. Toxicol Sci 180(1):38–50; doi: 10.1093/toxsci/kfaa187. PMID: 33404626.
View Abstract2020 (6 POSTS)
An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet
Bhat VS, Cohen SM, Gordon EB, Wood CE, Cullen JM, Harris MA, Proctor DM, Thompson CM. 2020. An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: A case study with hexavalent chromium, captan, and folpet. Crit Rev Toxicol 50(8)685-706; doi: 10.1080/10408444.2020.1823934.
View Abstract